Shares of Ultragenyx rebounded sharply after a one-day drop exceeding forty percent, climbing back into positive territory as investors responded to a reaffirmed overweight rating from Wells Fargo. Analyst Benjamin Burnett lowered his target from forty-five to twenty-eight dollars but emphasized an attractive risk-reward setup, citing upcoming feedback from the FDA on setrusumab’s bone mineral density data. With trading volume surging to nearly eleven million shares—well above the three-month daily average—buy orders dominated the tape by mid-afternoon, suggesting renewed confidence in management’s ability to navigate recent clinical setbacks.

Ultragenyx disclosed that both pivotal Phase 3 studies of setrusumab in osteogenesis imperfecta failed to achieve their primary goal of reducing fracture rates against placebo and bisphosphonate comparators. Despite robust secondary gains—statistically significant improvements in lumbar spine and total hip bone mineral density—the low incidence of fractures in control arms limited differentiation. The trials enrolled over two hundred patients across sixteen countries, and no new safety signals emerged. Management has initiated a comprehensive data review to explore subgroup effects and alternative endpoints before deciding on next steps for the program.

Ultragenyx announced completion of its rolling Biologics License Application for DTX401, an AAV-based gene therapy targeting Glycogen Storage Disease Type Ia. The submission package, covering chemistry, manufacturing and controls modules, builds on Phase 3 GlucoGene data from fifty-two treated patients with up to six years of follow-up. Those patients experienced marked reductions in daily cornstarch requirements, sustained euglycemia and improved fasting tolerance, translating into positive scores on the Patient Global Impression of Change instrument. DTX401 holds Rare Pediatric Disease, orphan drug, Fast Track and RMAT designations in the U.S., as well as orphan drug and PRIME designations in Europe, positioning it as a potential first-in-class treatment for this ultra-rare metabolic disorder.